Thank you, Mark. Yeah, look, I think the R&D cost line, just to be clear, has obviously the usual accounting treatment. So again, there's capitalization, there's amortization and so on. So quarter to quarter, I'm not sure what you're looking at, but at least quarter to quarter or sequentially, then the line may not move that much. We have a continued investment. We also allocate within priorities. So we've certainly pivoted more of our spending in R&D towards AI initiatives, be it on the product side to benefit our clients as well as on the efficiency side. So there's a range of different things. Some of the expense also is carried in operations where we're spending and investing to deploy the zone. Our proprietary service tool built on Salesforce technology that's rolling out AI infused and certainly helping. And then we have other You know examples floating around out there. I'll give you one example that in addition to what we mentioned in our prior remarks So in India, it's also year-end in India March 31. We We actually had a reduction. We do a lot of work for our clients validating tax tax Advantage sort of allowances and the receipts We actually deployed AI this year for the first time reduced the call volumes by 35% in the year-end process also reduced the labor by 35% and that was deployed against that sort of manual but very necessary compliance effort. So it's really a broad-based thing. We certainly have pointed our investment dollars in the direction of AI as well as the usual spend that we like to do to bring best-in-class products to market. And I wouldn't necessarily read too much into the sequential nature of the R&D program cost line in the P&L. Some of that can be accounting and some of that can be reallocation of dollars either within R&D or between R&D and operating costs.